Plain-English translation of NCT05472337 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication that reduces inflammation, can help your heart recover better after a heart attack. When doctors perform an angioplasty to open a blocked artery, sometimes the heart muscle doesn't get enough blood flow even after the artery is opened—this is called inadequate reperfusion. Researchers believe might reduce inflammation triggered during the procedure and help your heart heal more effectively.
Even with current best treatments for heart attacks, up to half of patients don't get enough blood flow back to the heart muscle after their artery is reopened. The procedure itself can trigger inflammation that damages tiny blood vessels in the heart, preventing full recovery. This study is testing whether this medication can reduce that inflammatory damage and improve outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to either receive plus standard heart attack treatment, or standard treatment alone for 6 weeks. You will take the medication (or placebo) as instructed while receiving all the usual care for your heart condition. The study team will monitor your progress and measure whether the medication helps improve blood flow to your heart muscle during this 6-week period.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Chile
Phase
Testing effectiveness
Sponsor
Pontificia Universidad Catolica de Chile
Collaborators
Fondo Nacional de Desarrollo Científico y Tecnológico, Chile
Enrollment target
~50 participants
Started
August 2022
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gonzalo Martínez, MD
Pontificia Universidad Catolica de Chile
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.